StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a report issued on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Barclays reduced their price target on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th.

Cellectis Trading Down 2.1 %

NASDAQ:CLLS opened at $1.87 on Wednesday. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The firm has a fifty day simple moving average of $2.01 and a 200-day simple moving average of $2.24. Cellectis has a 12 month low of $1.70 and a 12 month high of $3.77. The company has a market capitalization of $103.93 million, a P/E ratio of -1.44 and a beta of 3.10.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The firm had revenue of $18.05 million for the quarter, compared to analysts’ expectations of $5.00 million. During the same quarter in the previous year, the firm posted ($0.31) EPS. On average, equities research analysts anticipate that Cellectis will post -0.46 earnings per share for the current year.

Hedge Funds Weigh In On Cellectis

Several institutional investors and hedge funds have recently modified their holdings of the stock. XTX Topco Ltd acquired a new position in Cellectis in the second quarter valued at approximately $29,000. First Affirmative Financial Network purchased a new stake in Cellectis during the third quarter worth $45,000. Principal Financial Group Inc. grew its position in Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after buying an additional 12,467 shares during the period. Finally, Long Focus Capital Management LLC increased its holdings in Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after buying an additional 130,000 shares in the last quarter. Institutional investors and hedge funds own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.